ArticleCNS neuroscience & therapeutics2013
MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitin.
Article in CNS neuroscience & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 64 citations in OpenAlex.
- Emerging roles of prohibitins in cancer: an update.Cancer gene therapy · 2025Review
- The effects of hsa-mir-26a-5p on cell proliferation, migration, and PI3K inhibitor sensitivity in metformin-resistant triple negative breast cancer cells.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- Epigenetic Characteristics in Primary and Recurrent Glioblastoma-Influence on the Clinical Course.Biomedicines · 2024Article
- The Significant Role of microRNAs in Gliomas Angiogenesis: A Particular Focus on Molecular Mechanisms and Opportunities for Clinical Application.Cellular and molecular neurobiology · 2023Review
- MicroRNAs as prognostic markers and therapeutic targets in gliomas.Non-coding RNA research · 2022Review
- Human Microglia Extracellular Vesicles Derived from Different Microglia Cell Lines: Similarities and Differences.ACS omega · 2022Article
- Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma.Frontiers in cell and developmental biology · 2022Article
- Evaluation of a tumor electric field treatment system in a rat model of glioma.CNS neuroscience & therapeutics · 2020Article
- mTOR Modulates Intercellular Signals for Enlargement and Infiltration in Glioblastoma Multiforme.Cancers · 2020Review
- Small RNA profiles of HTLV-1 asymptomatic carriers with monoclonal and polyclonal rearrangement of the T-cell antigen receptor γ-chain using massively parallel sequencing: A pilot study.Oncology letters · 2020Article
- Prohibitin 1 in liver injury and cancer.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Exosomes derived from human CD34Stem cell research & therapy · 2019Article
- Circulating miR-141-3p, miR-143-3p and miR-200c-3p are differentially expressed in colorectal cancer and advanced adenomas.Molecular and clinical oncology · 2019Article
- Glioma stem cells-derived exosomal miR-26a promotes angiogenesis of microvessel endothelial cells in glioma.Journal of experimental & clinical cancer research : CR · 2019Article
- Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells.Translational oncology · 2019Article
- Diagnostic value of a microRNA signature panel in exosomes for patients with hepatocellular carcinoma.International journal of clinical and experimental pathology · 2019Article
- Differentiation antagonizing non-protein coding RNA modulates the proliferation, migration, and angiogenesis of glioma cells by targeting the miR-216a/LGR5 axis and the PI3K/AKT signaling pathway.OncoTargets and therapy · 2019Article
- Peptidylarginine Deiminases Post-Translationally Deiminate Prohibitin and Modulate Extracellular Vesicle Release and MicroRNAs in Glioblastoma Multiforme.International journal of molecular sciences · 2018Article
- MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability.American journal of physiology. Lung cellular and molecular physiology · 2018Article
- Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.Cell death & disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDS AND
aimsGlioma accounts for the majority of primary malignant brain tumors in adults. Upregulation of microRNA-26a (miR-26a) has been observed in glioma. However, the biological function and molecular mechanism of miR-26a in glioma remain to be elucidated.
methodsGlioma cells stably overexpressing or down-expressing miR-26a were analyzed for both in vitro and in vivo biological functions. Novel target of miR-26a was identified by bioinformatics searching and molecular biological assays. Glioma specimens and normal brain tissues were analyzed for both expression levels of miR-26a and its target.
resultsForced expression of miR-26a in glioma cells significantly increased both growth rate and colony formation in vitro and tumor growth and angiogenesis in vivo, while reduced expression of miR-26a played opposite roles. MiR-26a directly targeted prohibitin (PHB) whose expression levels were downregulated in glioma specimens. The levels of miR-26a were inversely correlated with PHB expression levels in glioma samples and strongly correlated with clinical WHO grades of glioma.
conclusionThese results reveal that miR-26a regulates PHB and promotes glioma progression both in vitro and in vivo and that miR-26a and its target PHB are associated with glioma development, which can be helpful in developing microRNA-based treatment for glioma in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.